In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with inadequately controlled schizophrenia did not achieve statistically ...

The phase-III pumping station of the Devadula Lift Irrigation Scheme was switched on by Irrigation Minister N. Uttam Kumar Reddy at Devannapet in Hanamkonda district on Thursday, marking a ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy (sacituzumab govitecan-hziy) and MSD’s Keytruda (pembrolizumab ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

LONDON, ON, April 15, 2025 /CNW/ - Abitibi Metals Corp. (CSE: AMQ) (OTCQB: AMQFF) (FSE: FW0) ("Abitibi" or the "Company") is pleased to announce the commencement of its fully funded Phase 3 drill ...

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus ...

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long list by many developers that can’t beat ...

Common Sense Oncology has developed principles designed to improve randomized phase 3 trials and ensure meaningful results. Recommendations address use of certain endpoints, toxicity reporting and ...

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial PR Newswire ...

In addition, in several predefined analyses on disease activity, OCREVUS IV 600 mg showed clinically meaningful results with the lowest annualised relapse rate (ARR) observed during the double-blind ...

The phase III ACHIEVE-1 study, the first of seven late-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes (T2D) and inadequate ...

announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 mg dose in people with ...